News

Merck's Verona Acquisition: Plugging A $4B Hole In A $20B Gap
Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...
Verona Pharma plc (VRNA): Jim Cramer Approves The Merck Acquisition
We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Verona Pharma plc (NASDAQ:VRNA) ...
These Stocks Are Moving the Most Today: Nvidia, AES, Verona Pharma, WPP, Bloom Energy, Aehr Test Systems, and More
Nvidia’s valuation crosses $4 trillion during Wednesday’s session, while AES stock rises sharply following a report that says ...
MedCity News4d
Merck Breathes Life Into Its Respiratory Prospects With $10B Deal to ...
Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive pulmonary disease. While Ohtuvayre is projected to become a blockbuster ...
Piper Sandler Lifts PT on Verona Pharma (VRNA) Stock, Maintains Overweight
Verona Pharma plc (NASDAQ:VRNA) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds. Piper ...
BioPharma Dive2d
With Verona deal, Merck wagers on strength of lung drug’s patents
The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...
Raleigh pharma's $10B sale pays off for Boston, NY investment firms
Investment firms in Boston and New York could see the biggest gains from the sale of a Raleigh drugmaker. Raleigh firm rides ...
Merck Acquires Verona Pharma for $10B to Support Portfolio with COPD Drug Ohtuvayre Ahead of Keytruda Patent Expiration
Merck & Co. Inc. (NYSE:MRK) is one of the most undervalued NYSE stocks to buy now. On July 9, Merck announced its acquisition ...